{
    "clinical_study": {
        "@rank": "19862", 
        "acronym": "INITIATE", 
        "arm_group": [
            {
                "arm_group_label": "Indacaterol", 
                "arm_group_type": "Experimental", 
                "description": "Indacaterol once daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for indacaterol and placebo for tiotropium once daily"
            }, 
            {
                "arm_group_label": "Tiotropium", 
                "arm_group_type": "Active Comparator", 
                "description": "Tiotropium"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will compare the efficacy of indacaterol versus placebo (i.e., rescue medication\n      only) and tiotropium in patients with Chronic Obstructive Pulmonary Disease (COPD) who have\n      not received maintenance COPD medication for at least 12 months prior to entry (described\n      hereafter as \"maintenance na\u00efve\", see inclusion criteria)."
        }, 
        "brief_title": "Comparison of Indacaterol With That of Placebo in 'Maintenance na\u00efve' Patients With COPD Using Blinded Tiotropium as Active Control", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease (COPD)", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose is to provide efficacy data comparing the long-acting beta-2 agonist,\n      indacaterol, with short-acting rescue therapy in maintenance-naive patients belonging to\n      GOLD 2011 Groups A and B."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with stable Chronic Obstructive Pulmonary Disease (COPD) Groups A or B\n             according to GOLD 2011.\n\n          -  Patients with a post-bronchodilator Forced Expiratory Volume in one second (FEV1)\n             \u226550% and <80% of the predicted normal, and post-bronchodilator FEV1/ Forced Vital\n             Capacity (FVC) < 0.7\n\n          -  Patients with no record of receipt of maintenance medication for COPD.\n\n          -  Patients with a mMRC dyspnea score \u22651 at Visit 2.\n\n          -  Current or ex-smokers who have a smoking history of at least 10 pack years.\n\n        Exclusion Criteria:\n\n          -  Patients who have not achieved acceptable spirometry results at run-in, in accordance\n             with American Thoracic Society (ATS) / European Respiratory Society (ERS) criteria\n             for acceptability and repeatability.\n\n          -  Patients who have had 2 or more COPD exacerbations that required treatment with\n             antibiotics, systemic steroids (oral or intravenous) or hospitalization in the 12\n             months prior to Visit 1.\n\n          -  Patients who have had a respiratory tract infection.\n\n          -  Patients requiring long-term oxygen therapy (>12 hours a day) on a daily basis.\n\n          -  Patients with a) any history of asthma, or b) onset of respiratory symptoms prior to\n             age 40 years.\n\n          -  Patients with allergic rhinitis who use a H1-antagonist or intra-nasal\n             corticosteroids intermittently.  Treatment with a stable dose is permitted.\n\n          -  Patients with concomitant pulmonary disease (e.g., lung fibrosis, sarcoidosis,\n             interstitial lung disorder, pulmonary hypertension) or active pulmonary tuberculosis\n\n          -  Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01715311", 
            "org_study_id": "CQAB149B2425", 
            "secondary_id": "2012-001536-59"
        }, 
        "intervention": [
            {
                "arm_group_label": "Indacaterol", 
                "description": "Indacaterol once daily via single-dose dry powder inhaler", 
                "intervention_name": "Indacaterol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Tiotropium"
                ], 
                "description": "Placebo to tiotropium capsules for inhalation once daily", 
                "intervention_name": "Placebo to tiotropium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tiotropium", 
                "description": "Tiotropium capsules for inhalation once daily", 
                "intervention_name": "Tiotropium", 
                "intervention_type": "Drug", 
                "other_name": "Tiotropium 18 mcg od via single-dose dry powder inhaler"
            }, 
            {
                "arm_group_label": [
                    "Indacaterol", 
                    "Placebo"
                ], 
                "description": "Placebo to indacaterol capsules for inhalation once daily", 
                "intervention_name": "Placebo to indacaterol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tiotropium"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "Chronic obstructive pulmonary disease", 
            "indacaterol", 
            "tiotropium"
        ], 
        "lastchanged_date": "February 5, 2013", 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-blind Placebo-controlled Study to Compare the Efficacy of Indacaterol With That of Placebo in Patients With COPD Who Have Not Previously Received Maintenance COPD Medication, Using Blinded Tiotropium as Active Control", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Therapeutic Goods Administration", 
                "India: Drugs Controller General of India", 
                "Korea: Food and Drug Administration", 
                "Philippines: Bureau of Food and Drugs", 
                "Czech Republic: State Institute for Drug Control", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: National Institute of Pharmacy", 
                "Israel: Ministry of Health", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Russia: Ministry of Health of the Russian Federation", 
                "South Africa: Medicines Control Council", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Ukraine: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy comparison of indacaterol to placebo (once daily treatment) by measuring Trough Forced Expiratory Volume in one second 24 hour postdose after 12 weeks of treatment.", 
            "measure": "Efficacy comparison of indacaterol to placebo", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01715311"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Effects comparison of indacaterol to placebo in terms of the patient-centric measurement St George's Respiratory Questionnaire for COPD (SGRQ- C) total score after 12 weeks of treatment.", 
                "measure": "St George's Respiratory Questionnaire for COPD (SGRQ- C) total score comparison between treatments", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Comparison of indacaterol to tiotropium using Trough Forced Expiratory Volume in one second.", 
                "measure": "Comparison of Forced Expiratory Volume in one second between indacaterol and tiotropium groups", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Effects comparison of indacaterol to tiotropium in terms of St George's Respiratory Questionnaire for COPD (SGRQ- C) total score after 12 weeks of treatment.", 
                "measure": "St George's Respiratory Questionnaire for COPD total score comparison between treatments", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "All adverse events will be reported", 
                "measure": "Adverse events and serious adverse events for all treatment groups", 
                "safety_issue": "Yes", 
                "time_frame": "week 12"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013", 
        "why_stopped": "withdrawn prior to patient recruitment"
    }
}